Aminoacidopatías

Main ideas / lessons from the talk

• The video is an educational presentation on inborn errors of metabolism that affect amino acid pathways.
• Many covered disorders share a key mechanism: accumulation of toxic metabolites, often causing neurological damage.
• The disorders are framed under a broader classification of inborn errors of metabolism into 3 groups (based on what level of the system is involved):
  1. Group 1: Intoxication — accumulation of substances due to failure of breakdown.
  2. Group 2: Energy-related defects — problems in mitochondrial and plasma energy processes.
  3. Group 3: Organelle defects — problems involving intracellular organelles.
• The presenters emphasize that amino-acid disorders covered here mainly fall into Group 1 (intoxications), where enzyme deficiencies cause metabolite buildup leading to poisoning, frequently neurotoxic.

---

Specific disorders covered (pathophysiology, diagnosis, treatment)

1) Phenylketonuria (PKU) / Hyperphenylalaninemia

Core concept / definition

• A group of conditions characterized by:
  • Elevated phenylalanine in blood: threshold given as > 2 mg/dL
  • Confirmation: persistent phenylalanine/tyrosine ratio > 3
• Autosomal recessive inheritance
  • Pregnancy recurrence risk mentioned: 25%

Causes

• ~98%: defects in phenylalanine hydroxylase (main enzyme defect)
• 1–2%: defects in enzymes related to the BH4/biotin-associated system (pathway details referenced as involving phenylalanine–tyrosine and biotin)

Pathophysiology

• Enzyme deficiency prevents conversion of phenylalanine → tyrosine.
• An alternative pathway increases formation of toxic metabolites (described as phenylacetate/lactate-like toxic acids).
• Consequences:
  • Neurotoxicity from accumulated compounds
  • Reduced tyrosine → impaired melanin synthesis → hypopigmentation
  • Altered neurotransmitter synthesis (e.g., dopamine-related effects) → neuropsychiatric risk

Severity classification (as presented)

• Classic PKU
  • Transcripts mention inconsistent thresholds for phenylalanine < 2 mg/dL, but repeatedly indicate:
  • Enzyme activity < 1%
  • Tolerance < 20 mg/kg
• Moderate form
  • Enzyme activity 3–50%
  • Tolerance ~20–25 mg/kg
• Mild hyperphenylalaninemia
  • Phenylalanine 2–4 mg/dL
  • Normal tyrosine
  • Enzyme activity > 50%
  • Often transient, may normalize by 6 months—but dietary management with monitoring is still recommended.

Clinical manifestations

• Impaired psychomotor development
• Seizures (including tonic-clonic)
• Hyperactivity and aggression
• Autism spectrum behaviors
• Possible external signs related to low melanin/tyrosine (example: blue eyes, light hair)
• Emphasis on neurotransmitter changes

Diagnosis

• Preferred: expanded newborn screening using tandem mass spectrometry
  • Dried blood spot on filter paper
  • Simultaneous measurement of many amino acids (including phenylalanine) + carnitine
• If not available:
  • Phenylalanine > 2 mg/dL (120 µmol/L) and Phe/Tyr ratio > 3
  • “Triglyceride factor” and biotin described as normal (as stated in transcript)
  • Urine metabolite analysis (text references phenyl/organic acids)
• Timing emphasis: diagnosis should be made before age 2 to prevent irreversible neurodamage.
• Molecular/genetic confirmation discussed (phenylalanine hydroxylase gene/enzymatic complex)

Treatment

• Restriction of the causative amino acid
  • Phenylalanine-free formula
  • Essential minerals
  • Tyrosine supplementation when needed
• Diet management
  • Avoid animal proteins:
    • meats, fish, shellfish, eggs, milk/dairy
  • Monitor foods with trace amounts:
    • cereals, potatoes, mixed vegetables
  • Permitted items (examples): sugar, oil, vegetable margarine, powdered fruit juices, cornstarch, condiments
  • Goal described broadly: low-protein diet
• Lifelong clinical follow-up with a multidisciplinary team:
  • pediatrics, neurology, psychology, nutrition, biochemistry
• Pregnancy-specific guidance
  • Maternal hyperphenylalaninemia can harm fetal development
  • Target maternal phenylalanine level: keep < 350 mg/dL (transcript inconsistent, same control idea repeated)
  • Controlled range mentioned: 120–360 µmol/L
  • Fetal risks stated:
    • >90% intellectual development disorders
    • microcephaly ~5–18%
    • congenital heart defects ~12%
• Special management points
  • Avoid syrups with aspartame
  • If surgery/fasting occurs (catabolic state):
    • consult the pediatrician beforehand
    • avoid prolonged fasting; adjust feeding
    • refeed with specialized formula (numerical details given but somewhat garbled)

---

2) Tyrosinemia

Core concept

• Congenital metabolic disorder with accumulation of tyrosine and metabolites due to enzyme deficiencies.
• The talk stresses downstream effects on liver/kidneys and broader roles of tyrosine (catecholamines, thyroid hormones, melanin-related pathways).

Types described

• Type 1: liver/kidney dominant
  • Defects in tyrosine catabolism pathway enzymes (transcript references tyrosine aminotransferase and downstream toxic intermediates).
• Type 2: oculocutaneous (also described as “Kirchner-Hart syndrome”)
  • Different enzyme step defect; characteristic eye/skin manifestations.
• Type 3: rarer
  • Primarily neurological presentation.

Pathophysiology (as described)

• Toxic intermediates cause:
  • Liver injury
  • Long-term neoplastic degeneration (liver cancer risk emphasized)
  • Neurotoxicity from metabolite effects (alkylating effects referenced)

Clinical presentation

• Acute form
  • Onset in the first weeks of life
  • Liver failure symptoms: irritability, vomiting/diarrhea, hypoglycemia, coagulopathy
  • “Rotten cabbage/bone” odor mentioned
• Chronic form
  • Progressive liver failure → cancer risk
  • Renal issues (e.g., rickets; adenocarcinoma mentioned)
  • Neuro issues and severe abdominal pain mimicking appendicitis
  • Behavioral problems including self-mutilation (as described)
• Fanconi syndrome discussion
  • Renal tubular dysfunction:
    • amino acids, glucose, phosphates lost in urine
    • metabolic acidosis and polyuria mentioned
  • Mainly in chronic form (liver disease precedes it)
  • Management priority:
    • remove offending metabolite
    • replace lost electrolytes
    • phosphate/vitamin supplementation when indicated

Diagnosis

• Biochemical focus:
  • urine markers including organic acids (specific ones referenced in the transcript)
  • plasma tyrosine level emphasis (very high thresholds mentioned)
  • liver/kidney involvement signaled by labs
• Prenatal diagnosis:
  • genetic study and/or ultrasound mentioned

Treatment methodology / instructions

• Core strategy: dietary restriction
  • restrict protein
  • restrict phenylalanine and tyrosine (as described for this disorder’s management approach)
• Parenteral nutritional support as needed (stage-based support referenced)
• Type 1 specific medical therapy
  • Drug described as a potent inhibitor of an enzyme (targeted pharmacologic inhibition referenced)
• Liver transplantation
  • mentioned for severe hepatic involvement
• Type 2 / Type 3
  • diagnosis based on symptoms/labs; treatment centered on the dietary restriction principles and metabolic patterns

---

3) Alkaptonuria / “Homogentisic acid” disorder (“cantor night” mentioned)

Core concept

• Congenital error of amino acid metabolism causing:
  • accumulation of homogentisic acid
  • dark urine (key early clue)
  • connective tissue pigmentation
  • degenerative changes, especially joint/structural degeneration

Diagnosis

• Suspected from:
  • early dark urine
  • skin/connective tissue symptoms
• Confirmed by:
  • detecting homogentisic acid in plasma
• Genetic confirmation and counseling noted

Treatment

• No effective curative therapy stated
• Palliative management only
  • low-protein diet
  • physiotherapy
  • joint replacement surgery when needed
  • pain management

---

4) Homocystinuria

Core concept

• Inborn error where homocysteine accumulates in:
  • CNS
  • vascular system
  • skeletal system
  • ocular systems
• Discussed as a methyl-group related metabolic role issue involving sulfur-containing amino acids.

Causes / types

• At least five genes implicated (mutations in at least five genes stated).
• Three types described:
  • Type 1 (classic): deficiency of cystathionine β-synthase
  • Type 2: folate reductase deficiency
  • Type 3: vitamin B12 metabolism defect

Associated factors (besides genetics)

• Age/sex/menopause, smoking, inactivity, diseases, nutritional deficiencies
• Drugs inhibiting the pathway mentioned (details not specified in transcript)

Pathophysiology

• Excess homocysteine → oxidative stress and endothelial injury
• Increases atherosclerosis and thrombosis risk
• Mechanistic steps described:
  • decreased nitric oxide production
  • smooth muscle proliferation
  • fibrotic deposits
  • macrovascular obstruction

Clinical features

• Altered growth/development
• Marfan-like habits mentioned
• Early osteoporosis; scoliosis and pathological fractures
• Eye lens changes (lens lower position described; contrasted with Marfan in transcript)
• Increased thromboembolic risk and premature atherosclerosis
• Intellectual disability reported in ~60% (often not severe, as stated)

Diagnosis

• Elevated homocysteine and methionine in blood
• Decreased cystine-related measures and possibly phosphate levels (wording as in transcript)
• Hyperhomocysteinemia categories mentioned:
  • 15–30 µmol/L: normal range
  • 37–100 µmol/L: intermediate
  • >100 µmol/L: hyperhomocysteinemia
• Confirmation with enzyme activity and/or genetic study mentioned

Prenatal diagnosis

• First trimester:
  • molecular techniques if parental mutations are known
  • otherwise enzymatic activity estimates and methionine elevation approach (as described)

Treatment methodology / instructions

• Goal: keep homocysteine < 50 µmol/L
• Dietary approach:
  • restrict methionine
  • use high biological value proteins (animal origin mentioned)
  • supplement other amino acids excluding methionine
• Vitamin response strategy:
  • Pyridoxine (vitamin B6) in pyridoxine-responsive cases (dose range referenced)
  • if not responsive: betaine (transcript says “Aheta”)
• Monitor pathway-related vitamins:
  • vitamin B2 and folic acid
• Emphasize cardiovascular/thromboembolic risk management with closer monitoring

---

5) Maple Syrup Urine Disease (MSUD)

Core concept

• Defective activity of a multi-enzyme dehydrogenase complex that metabolizes branched-chain essential amino acids:
  • leucine, isoleucine, valine
• Accumulation causes:
  • psychomotor retardation, feeding problems
  • characteristic maple syrup odor in urine
  • neurotoxicity, especially from leucine-related toxicity (as stated)

Clinical classifications (forms)

1. Classic MSUD
   • Onset: day 5–10
   • Enzyme activity: 0–2%
   • Symptoms: vomiting, lethargy, dystonia, acidosis, seizures
   • Maple syrup odor; amino acid accumulation in urine/skin possible
2. Intermediate MSUD
   • Onset: about 5 months
   • Symptoms: anorexia, chronic diarrhea, impaired growth, mental retardation
   • Enzyme activity: 3–30%
3. Intermittent MSUD
   • Normal early development
   • Episodes triggered by:
     • catabolic events (infection)
     • high protein intake
   • During symptomatic periods: increased branched-chain amino acids
   • Enzyme activity: 5–20%
4. Thiamine-responsive variants
   • Some forms improve with thiamine
   • Transcript also mentions a late variant and thiamine-responsive classification concept

Diagnosis

• Early measurement:
  • branched-chain amino acids
  • alkaline phosphatase mentioned
• Emphasis: early diagnosis prevents severe neurological sequelae.
• Newborn screening approach:
  • blood smear on dried paper mentioned
  • sample timing: after 12 hours of life because earlier values are unreliable (as stated)

Treatment methodology / instructions

Two pillars:

1. Restriction of branched-chain amino acids
   • tailored to age and daily protein/calorie requirements
2. Manage acute metabolic decompensations
   • depends on consciousness status

If impaired consciousness

• More aggressive strategy:
  • strict fluid control; consider diuretics if needed for edema control
  • suspend previous feeding
  • caloric regimen:
    • 120–140 kcal/kg/day
    • 40–50% lipids
    • amino acids: 3–4 g/kg/day of essential/non-essential amino acids (plus additional lysine described)
  • objective: dilute leucine to > 750 µmol/L within 24 hours
  • then transition to specialized formulas lacking the 3 branched-chain amino acids

If no impaired consciousness

• Start specialized formulas immediately.

Expected outcomes stated

• Leucine levels 100–300 µmol/L
• Weight gain 20–30 g/day
• Growth percentile improvement (as stated)

---

Speakers / sources featured

• María Castro — presenter; medical student (first semester), University of Caldas; member of the Pediatric Research Group at University of Caldas.
• Ángel and Pega — referenced at the start of the talk (roles not clearly specified).
• Mar and Alandia Londoño (“Sol”) — additional student presenters mentioned; associated with University of Caldas (semester indicated as “next semester”).
• Conference / organizer (implied) — transcript references a conference link and YouTube description, but no additional named source provided.